Navigation Links
Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Date:9/18/2009

SAN FRANCISCO, Sept. 18 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced the Second and final closing of a private placement financing with aggregate gross proceeds of US $5,611,475, exceeding the target of US $5 million.

As previously reported, the net proceeds of the private placement will be used to continue advancing the Company's clinical development programs with the lead product JX-594. Key value creating milestones planned for the next 12 months include completion of a randomized Phase II trial in liver cancer, followed by initiation of a pivotal Phase III trial in liver cancer. In addition, Jennerex plans to complete a Phase I trial in solid cancers (including lung and colorectal), followed by initiation of a Phase II colorectal cancer trial. Proceeds will also be used for manufacturing, general corporate purposes and to augment working capital.

"This Series C was a success due both to continued investment from many of our current Shareholders, as well as support from a number of important new investors. We are particularly pleased to welcome the Ottawa Regional Cancer Foundation as a significant new investor," said David H. Kirn, M.D., President and CEO. "Jennerex and the Foundation share a common vision of extending and preserving the lives of patients with cancer. We also share a common commitment to build on the great strength of biological research and world-class facilities at the Ottawa Hospital Research Institute (OHRI). The Cancer Foundation's participation will further support and extend the scope of joint research and development activities being undertaken in partnership with Jennerex at the OHRI, including expansion of manufacturing and clinical trial activities," said Dr. Kirn.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
6. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
7. EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application
8. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
9. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
10. Pacific Biometrics Completes $4 Million Debt Financing
11. Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... MENLO PARK, Calif. , May 23, 2013 /PRNewswire/ ... an oral treatment for pain has reached an important ... clinical trial of VBY-036 - a selective cathepsin S ... of VBY-036 is a double-blind, randomized, placebo-controlled study designed ... escalating doses of VBY-036 in healthy adults. ...
(Date:5/23/2013)... Z Trim Holdings, Inc. (OTC Markets: ZTHO), ... of industries, announced that Chef Erin Ryan ... year,s National Restaurant Association ("NRA") NRA Show, which was ... Research Chefs Association.  Chef Ryan spoke on the subject ... and the Ugly," joining four other prestigious panelists including: ...
(Date:5/23/2013)... May 23, 2013 Pressure BioSciences, Inc. (OTCQB: ... Company will host a teleconference to discuss its First ... update. The teleconference information is provided below: ... Daylight Time (EDT) Dial-in: (800) 875-3456 (U.S.); ... (Int,l) Passcode: VS22823 For those unable to ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... , , SAN ... J. Fox Foundation will provide partial funds for long-term follow-up testing ... for Parkinson,s disease. The funding will enable Ceregene to collect ... patients with advanced Parkinson,s disease who were enrolled in the double-blind, ...
... , , , , ... OPTR ) today reported financial results for the second quarter ended June ... of 2009 of $12.4 million, or $0.37 per share, which was in ... the second quarter of 2008 of $8.1 million, or $0.29 per share. ...
... Inc. (NASDAQ: AEZS , TSX: AEZ), a global ... its second quarter 2009 financial and operating results before market ... a conference call and webcast to discuss these results later ... may access the live webcast via the Company,s website at ...
Cached Biology Technology:Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 3Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 4Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 5Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 6
(Date:5/23/2013)... pathogens are growing increasingly resistant to the conventional antibiotics ... scientists has synthesized a potent new class of compounds ... , Writing online in the Journal of the ... of Wisconsin-Madison chemistry Professor Helen Blackwell describes agents that ... Staphylococcus aureus , a bacterium at the root of ...
(Date:5/22/2013)... cell powered buses, including a team from Simon ... processes and bus membrane durability. , The team ... in the operating cycle of the bus on ... study, led by SFU graduate student Natalia MaCauley, ... Burnaby-based Ballard Power Systems and funded by Automotive ...
(Date:5/22/2013)... (May 22, 2013)The omega 3 fatty acids in fish ... diseaseso much so that the American Heart Association currently ... week, particularly fatty varieties rich in omega 3s. However, ... mystery. In a new study, scientists led by Jason ... this phenomenon by providing evidence that fish oil might ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2
... your goal, you can't do better than to emulate a ... an unusual pitching stroke that allows the bug to hover ... a marvel of engineering. , Z. Jane Wang, professor of ... on flying systems and fluid dynamics today (Feb. 19) at ...
... drinkers who continue to imbibe after learning they are pregnant ... to those of abstainers or quitters, says a new study. ... the findings reveal effects of drinking on the developing human ... Alcoholism: Clinical and Experimental Research . , "What ...
... mention the cleaning product industry, repeatedly warn of their ... is raising the intriguing idea that persistent bacterial and ... Robert W. and Vivian K. Cahill Professor in Cancer ... an essay in the Feb. 24 issue of the ...
Cached Biology News:Scientist uses dragonflies to better understand flight 2Ultrasounds show mothers' drinking shrinks fetal brain 2Scientists look to the Bahamas as a model for coral reef conservation 2Scientists look to the Bahamas as a model for coral reef conservation 3